2-(3-(3,5-Dimethyltriazol-4-Yl)-5-((S)-Oxan-4-Yl(Phenyl)Methyl)Pyrido(3,2-B)Indol-7-Yl)Propan-2-Ol

2 trials 1 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

2 Sponsors

8 Countries

Phase I/II

Phase I/II: 2

Indications tested

Myelofibrosis 1

Sponsors using this IMP

Bristol-Myers Squibb Services Unlimited Company 1 Celgene Corp. 1

All trials

2 total

Phase 1b/2a Study to Evaluate CC-92480 (BMS-986348) in Combination with Other Treatments in Relapsed or Refractory Multiple Myeloma Recruiting

2023-509384-25-00 Phase I/II 2 countries Celgene Corp.
A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi… Ended

2023-509635-89-00 Phase I/II 7 countries Bristol-Myers Squibb Services Unlimited Company

Showing 1–2 of 2 trials

← All drugs A–Z